Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT07594587
Recruiting Observational

A Study of Ruxolitinib in Patients With Graft-Versus Host Disease

NCT07594587 · tracked via the Priya Life Science Japan tracker
Sponsor
Novartis Pharmaceuticals
Phase
Observational
Started
2026-05-11
Last updated
2026-06-08

Condition(s) studied

Graft-Versus-Host Disease

Study summary

This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.

Eligibility

Sex
ALL
Min age
0 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with acute and chronic GVHD * Patients treated with ruxolitinib Exclusion Criteria: None Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcome measure(s)

  • Number and Percentage of Patients With Common Terminology Criteria for Adverse Event (CTCAE) Grade ≥ 3 Infections — Up to 1 year
    Grade ≥ 3 infections according to the CTCAE v5.0.
  • Number and Percentage of Deaths Due to Infection — Up to 1 year
  • Time to First Event — Up to 1 year
    Time to first event is defined as the time from the start date of treatment with ruxolitinib to the first onset date of infection. Grade ≥ 4 infections according to the CTCAE v5.0.

Trial sites (1)

FacilityCityRegionStatus
Novartis Tokyo Japan Recruiting

More Novartis Pharmaceuticals trials in Japan

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. Recruiting
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS Recruiting
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease Active, not recruiting
Study of Out of Specification for Tisagenlecleucel Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07594587 on ClinicalTrials.gov ↗ ← All trials in Japan